Skip to main content

Table 4 Surgery and pathological staging for patients

From: Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy

Characteristics Overall (n = 123)
Time from NCRT to surgery (weeks), median (IQR) 6.7 (5.4–8.3)
Pathological T stage, n (%)
 pT0 52 (42.3)
 pT1 15 (12.2)
 pT2 19 (15.4)
 pT3 35 (28.5)
 pT4a 2 (1.6)
Pathological N stage, n (%)
 pN0 82 (66.7)
 pN1 24 (19.5)
 pN2 13 (10.6)
 pN3 4 (3.3)
Pathological TNM stage, n (%)
 pT0N0 46 (37.4)
 I 14 (11.4)
 II 33 (26.8)
 III 30 (24.4)
Tumor regression grade, n (%)
 0 46 (37.4)
 1 11 (8.9)
 2 60 (48.8)
 3 6 (4.9)
R0 resection, n (%)
 All location 104 (84.6)
 Upper 18 (14.6)a
 Middle 48 (39.0)a
 Lower 38 (30.9)a
  1. Abbreviations: NCRT neoadjuvant chemoradiotherapy, IQR interquartile range
  2. aLocation specific R0 resection rate: upper (75.0%), middle (81.7%), lower (94.9%)